RMAT Designations

The Regenerative Medicine Advanced Therapy (RMAT) designation, established by the 21st Cure Act in late 2016, offers similar benefits to the FDA's breakthrough therapy designation (BTD), including increased communication during development through early interactions with the agency, guidance and organizational commitment. The RMAT is designed for cell and tissue therapies for serious illness with preliminary evidence of an effect on unmet medical needs. Updated weekly.